TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Memphasys Ltd ( (AU:MEM) ) is now available.
Memphasys Limited announced changes in its board of directors, with Mr. Mathew Watkins appointed and Mr. David Ali ceasing as directors. The company acknowledged an administrative oversight in the timely filing of director interest notices but assured that current compliance arrangements are adequate. These changes are not expected to impact the company’s operations or compliance with ASX listing rules.
More about Memphasys Ltd
Memphasys Limited is an Australian-based reproductive biotechnology company that commercializes the Felix™ System, a patented bioseparation technology designed to isolate the most viable sperm cells for human assisted reproduction. The system improves sperm quality and reduces laboratory time by replacing traditional centrifugation with a faster, gentler, and standardized sperm selection process. Memphasys aims to establish Felix™ as a global standard in sperm preparation for IVF through direct and distribution-led sales channels.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.46M
For a thorough assessment of MEM stock, go to TipRanks’ Stock Analysis page.